Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper

Industry Insight by 2FIRSTS
Apr.15.2024
Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
JAMA retracts e-cigarette quitting study for major coding errors and doubts on accuracy, causing widespread concern and controversy.

Recently, the Journal of the American Medical Association (JAMA) retracted an article published two months ago about vaping e-cigarettes due to researchers notifying the editors of "significant coding errors" and other issues in the study.

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal page | Image source: American Medical Association Journal

 

This paper titled "Effectiveness of e-cigarettes compared with varenicline and nicotine gum for smoking cessation: a randomized clinical trial" was originally published in the January 29th issue of JAMA Internal Medicine, led by Dr. Liu Zhaobo from the Smoking Control and Respiratory Disease Prevention Department at Beijing Friendship Hospital. The researchers in this study found that in terms of helping people quit smoking, using e-cigarettes is not inferior to prescription medications and is more effective than nicotine gum. The paper has garnered widespread attention in the medical community, non-professional media, and social media.

 

Top Medical Journal Retracts E-Cigarette Smoking Cessation Effectiveness Paper
Withdrawal notice | Image source: Journal of the American Medical Association

 

However, the article was later retracted.

 

The retraction notice for this paper was issued on March 29th as follows:

 

We have identified significant coding errors that are difficult to correct. We also found discrepancies in the calculations, which have raised doubts about the accuracy and reliability of the reported results. Therefore, we believe it is necessary to retract this article in order to maintain the integrity of scientific research and uphold the trust of our readers and the medical community. All co-authors have agreed to the retraction. We sincerely apologize for any inconvenience or confusion this may have caused.

 

According to the academic media Research Gate, Liu Zhao later responded to media inquiries via email, stating that the article was voluntarily retracted by the research team. He provided the following explanation in response:

 

As we explained to the editors of the Journal of the American Medical Association, following the publication of this paper, we plan to conduct a secondary analysis. In this process, we discovered that 109 participants who should have been in the NRT group were incorrectly placed in the EC group, and another 109 participants who should have been in the EC group were incorrectly placed in the NRT group. We immediately conducted an analysis and found that the main results had changed, therefore, we promptly wrote a letter to the editor explaining this issue and requesting the retraction of the paper.

 

Furthermore, according to publicly available information, no other articles have been affected by these issues. According to Clarivate's Web of Science, the research findings in question have been cited once.

 

Dr. Liu Chaobo, the first author of the paper by the group called 2FIRSTS, was contacted for details regarding the withdrawal notice. Dr. Liu stated that the withdrawal notice was clearly explained and no further information could be disclosed. Additionally, a call was made to the Tobacco Control and Cessation Center at the China-Japan Friendship Hospital to inquire about the details, but the staff member who answered the call claimed to be unaware of the situation.

 

2FIRSTS will continue to follow the latest developments on the research paper and its retraction.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Altria Q2 2025: E-cigarette Unit Posts $108M Operating Loss; Nicotine Pouch on! Grows 26.5%
Altria Q2 2025: E-cigarette Unit Posts $108M Operating Loss; Nicotine Pouch on! Grows 26.5%
Altria Group 2025 disclosed on July 30, 2025, Q2 net income of $6.102 billion, down 1.7% year-over-year, and adjusted diluted EPS of $1.44, up 8.3% year-over-year, while first-half net income of $11.361 billion was down 3.6% year-over-year, and adjusted diluted EPS of $2.67, up 7.2% year-over-year.
Jul.31 by 2FIRSTS.ai
PMI Launches Global Smoke-Free Travel Information Platform: 2Firsts Shares User Insights and Trend Analysis
PMI Launches Global Smoke-Free Travel Information Platform: 2Firsts Shares User Insights and Trend Analysis
Philip Morris International(PMI) has launched the world’s first smoke-free travel platform to address information gaps and regulatory uncertainties for adult nicotine users. 2Firsts reviews its age verification, journey-focused interface, advanced search, and user support, highlighting how it helps adults make compliant cross-border purchases.
Jul.11 by 2FIRSTS.ai
SKE Launches New CL2000 Refillable Pod Vape in the UK with 1.8mL + 2.2mL Dual-Pod Design
SKE Launches New CL2000 Refillable Pod Vape in the UK with 1.8mL + 2.2mL Dual-Pod Design
The SKE CL2000 e-cigarette features a dual-pod setup combining 1.8mL and 2.2mL capacities, delivering a total of 2,000 puffs. The brand claims it is equipped with a “plug-and-play pod system with auto-refill technology.” The product has been listed with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and will soon be available through UK distributors at a retail price of around £10.99.
Aug.14 by 2FIRSTS.ai
Malaysia's Perak State Plans to Implement E-Cigarette Ban in October, Health Department Accelerates Drafting of Policy Document
Malaysia's Perak State Plans to Implement E-Cigarette Ban in October, Health Department Accelerates Drafting of Policy Document
Malaysia's Perak state government plans to enforce a statewide ban on e-cigarettes in October to improve public health.
Jun.23 by 2FIRSTS.ai
Indian Anti-Vape Group: Weak Enforcement of Vape Ban as Online and Black Market Sales Surge
Indian Anti-Vape Group: Weak Enforcement of Vape Ban as Online and Black Market Sales Surge
Indian medical experts and the group Mothers Against Vaping warn that e-cigarettes damage youth heart, lung, and mental health. Despite the 2019 ban, vaping products remain available via underground markets. They call on the government to tighten digital platform regulation and adopt stricter international controls.
Jul.08
Roanoke City Council Considers $20,000 Annual Fee for Vape Shops, Sparking Debate
Roanoke City Council Considers $20,000 Annual Fee for Vape Shops, Sparking Debate
ROANOKE, Virginia — August 11, 2025 — The Roanoke City Council is reviewing a proposal that would require vape shops whose primary business is selling e-cigarette products to pay an annual operating fee of $20,000. The measure would not apply to gas stations or convenience stores that also sell vaping products.
Aug.14 by 2FIRSTS.ai